Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen
OBJECTIVE: To retrospectively evaluate the utility of serum and cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) as biomarkers for spinal muscular atrophy (SMA) progression and response to nusinersen treatment.
METHODS: NfL and pNfH levels were quantified using single molecular array (SIMOA) in CSF of 33 adult SMA patients (SMN copy number 3-5) before and in response to nusinersen treatment. In 11 of the patients, blood serum samples were also collected. CSF NfL and pNfH from patients were compared to CSF Nfs from age-matched controls without neurological disease (n = 6). For patients, pearson correlation coefficients (r) were calculated to investigate associations between Nf levels and other functional outcome measures.
RESULTS: Nf levels were similar between SMA and control adults and showed no change in response to nusinersen treatment in CSF or serum. Cross-sectional analyses showed an increase in CSF NfL and pNfH with age in patients (NfL p = 0.0013; pNfH p = 0.0035) and an increase in CSF NfL in controls (p = 0.002). In non-ambulatory patients, baseline serum pNfH showed a negative correlation with multiple strength and functional assessment metrics including Revised Upper Limb Module (r = -0.822, p = 0.04), upper extremity strength (r = -0.828, p = 0.042), lower extremity strength (r = -0.860, p = 0.028), and total strength (r = -0.870, p = 0.024).
CONCLUSIONS: Nf levels did not change in response to nusinersen in adults with SMA and were not different from controls. In patients and controls, we detected an age-related increase in baseline CSF NfL and pNfH levels. Though some associations were identified, our results suggest Nf levels are not preditive or prognostic biomarkers in this population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of neuromuscular diseases - 9(2022), 1 vom: 31., Seite 111-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rich, Kelly A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5Z9SP3X666 |
|---|
| Anmerkungen: |
Date Completed 21.02.2022 Date Revised 21.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JND-210735 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333141687 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333141687 | ||
| 003 | DE-627 | ||
| 005 | 20231225221033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JND-210735 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333141687 | ||
| 035 | |a (NLM)34776417 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rich, Kelly A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2022 | ||
| 500 | |a Date Revised 21.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To retrospectively evaluate the utility of serum and cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) as biomarkers for spinal muscular atrophy (SMA) progression and response to nusinersen treatment | ||
| 520 | |a METHODS: NfL and pNfH levels were quantified using single molecular array (SIMOA) in CSF of 33 adult SMA patients (SMN copy number 3-5) before and in response to nusinersen treatment. In 11 of the patients, blood serum samples were also collected. CSF NfL and pNfH from patients were compared to CSF Nfs from age-matched controls without neurological disease (n = 6). For patients, pearson correlation coefficients (r) were calculated to investigate associations between Nf levels and other functional outcome measures | ||
| 520 | |a RESULTS: Nf levels were similar between SMA and control adults and showed no change in response to nusinersen treatment in CSF or serum. Cross-sectional analyses showed an increase in CSF NfL and pNfH with age in patients (NfL p = 0.0013; pNfH p = 0.0035) and an increase in CSF NfL in controls (p = 0.002). In non-ambulatory patients, baseline serum pNfH showed a negative correlation with multiple strength and functional assessment metrics including Revised Upper Limb Module (r = -0.822, p = 0.04), upper extremity strength (r = -0.828, p = 0.042), lower extremity strength (r = -0.860, p = 0.028), and total strength (r = -0.870, p = 0.024) | ||
| 520 | |a CONCLUSIONS: Nf levels did not change in response to nusinersen in adults with SMA and were not different from controls. In patients and controls, we detected an age-related increase in baseline CSF NfL and pNfH levels. Though some associations were identified, our results suggest Nf levels are not preditive or prognostic biomarkers in this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult spinal muscular atrophy | |
| 650 | 4 | |a aging | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a neurofilament protein | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Neurofilament Proteins |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 650 | 7 | |a neurofilament protein L |2 NLM | |
| 650 | 7 | |a nusinersen |2 NLM | |
| 650 | 7 | |a 5Z9SP3X666 |2 NLM | |
| 700 | 1 | |a Fox, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Yalvac, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Heintzman, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Tellez, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bartlett, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Severyn, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Linsenmayer, Mathew |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Jerry |e verfasserin |4 aut | |
| 700 | 1 | |a Sterling, Gary Brent |e verfasserin |4 aut | |
| 700 | 1 | |a Weaver, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Rajneesh, Kiran |e verfasserin |4 aut | |
| 700 | 1 | |a Pino, Megan G |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, W David |e verfasserin |4 aut | |
| 700 | 1 | |a Elsheikh, Bakri |e verfasserin |4 aut | |
| 700 | 1 | |a Kolb, Stephen J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuromuscular diseases |d 2014 |g 9(2022), 1 vom: 31., Seite 111-119 |w (DE-627)NLM246466057 |x 2214-3599 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:1 |g day:31 |g pages:111-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JND-210735 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 1 |b 31 |h 111-119 | ||